{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-26-000006","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.538957+00:00","generated_at":"2026-05-16T03:30:47.225384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised","bullets":["Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).","TAVR sales $1.16B (+12.0%); TMTT sales $156M (+40%). Full-year sales growth 11.5%.","FY2026 outlook: constant-currency sales growth 8–10%, adjusted EPS $2.90–$3.05.","FDA approved SAPIEN M3, first transcatheter mitral replacement; CMS opened TAVR NCD reconsideration.","Q1 2026 guidance: sales $1.55–$1.63B, adjusted EPS $0.70–$0.76."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-26-000006","json":"https://secwatch.observer/filing/0001099800-26-000006.json","markdown":"https://secwatch.observer/filing/0001099800-26-000006.md","text":"https://secwatch.observer/filing/0001099800-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/0001099800-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/ew-20260210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:30:47.225384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}